CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that managem ...
NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results